Importantly, higher intratumoral expression of CMKLR1 has a beneficial effect both on overall survival (OS) (p = 0.002, HR = 0.8 (0.7–0.92)) and on progression-free survival (PFS) (p = 0.026, HR = 0.86 (0.76–0.98) in ovarian cancer patients [36]. Here, CMKLR1 is linked to ovarian carcinoma.